New Product Release: Nitazenes Array is now available on the Evidence MultiSTAT. Find out more here

[mpc_image image=”9200″ image_size=”full” force_fullwidth=”true” image_opacity=”100″ image_inner_border_gap=”0″ effect=”none” image_hover_opacity=”100″]

Nitazenes Test

nitazenes test detection panel

Nitazenes are a powerful new class of synthetic opioids, often hundreds of times stronger than morphine, and are missed by traditional drug screens, creating a major challenge for healthcare and law enforcement. To combat this, Randox have developed the world’s first immunoassay nitazenes test for urine samples.

Why Choose the Evidence MultiSTAT for Nitazenes Screening?

nitazenes test detection panel

First To Market
The only product on the market
that can test for nitazenes in
urine in <20 minutes.

nitazenes test detection panel

Keep Communities Safe
Our rapid results allow you to get
information out quickly to local
authorities and public health.

Randox Evidence MultiSTAT system performing nitazenes test

Highly Accurate Results
Biochip results are comparable to
confirmatory testing, providing you with reliable results you can trust.

Randox Evidence MultiSTAT system performing nitazenes test

Fully Automated Ease of Use
The Evidence MultiSTAT is a fully
automated analyser; simply load the
sample and press start.

Randox Evidence MultiSTAT system performing nitazenes test

Large Detection Range
Detect up to 10 different nitazenes
and their metabolites due to our
assay cross-reactivity.

Catalogue Number: EV4658

How Nitazenes Are Typically Detected

Until now, nitazenes have typically been detected through either lateral flow test strips, which have a high rate of false positives, or LC-MS/MS confirmatory testing, which is highly specialised and significantly more expensive.

Randox Nitazene test is the world’s first immunoassay test for nitazenes in urine. Detecting up to 10 nitazene analogues in under 20 minutes via assay cross-reactivity, with results comparable to confirmatory LC‑MS/MS testing. Randox’s rapid Nitazenes test provides a fully automated process via the Evidence MultiSTAT analyser, drastically improving the synthetic opioid screening landscape.

How the Randox Nitazenes Test Works

nitazenes test detection panel

Why Standard Opioid Panels Miss Nitazenes

Most routine opioid immunoassays are designed to detect opioids that resemble morphine, heroin, codeine, or fentanyl. Nitazenes, however, belong to the 2‑benzylbenzimidazole class and look nothing like these drugs at the molecular level.

Because of this structural difference, they do not bind to the antibodies used in standard opioid and synthetic opioid screens, so the test does not register a positive result.

Randox Nitazene test has been specifically designed to test for up to 10 nitazene analogues and is standardised to Isotonitazene, providing a highly sensitive and precise screen for nitazenes.

Nitazene Analogues Detected

Nitazenes
IsotonitazeneEtonitazeneProtonitazene
ClonitazeneN-Pyrrolidino EtonitazeneN-Pyrrolidino Metonitazene
MetonitazeneN-Desethyl IsotonitazeneButonitazene
N-Pyrrolidino Protonitazene--

Why Nitazenes Testing Matters

Detection Challenges

Detection Challenges

Standard opioid tests do not detect nitazenes.

Until now, testing required advanced techniques such as LC-MS/MS.

Emerging Threat

Emerging Threat

Increasingly found in post-mortem toxicology cases.

Often mixed with other drugs like fentanyl, heroin, or counterfeit pills.

Global Spread

Global Spread

Detected in Europe, North America, Asia, and South America.

The UK recorded 400 nitazene-related deaths between June 2023 and January 2025.

In the U.S., 320 overdose deaths in 2023 reportedly involved nitazenes, according to the World Drug Report. However, this number is likely understated.

Catalogue Number: EV4658

Request Demo